Palmetto GBA Issues Three Draft LCDs on Multi-marker Tests; MolDx Lays out Review Criteria, Process | GenomeWeb

NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA has issued draft local coverage determinations stipulating reimbursement criteria for three multi-marker molecular diagnostics: Assurex Health's pharmacogenetic test for refractory depression, MDxHealth's ConfirmMDx epigenetic prostate cancer test, and bioTheranostics' Breast Cancer Index test for gauging disease recurrence.

Stakeholders may comment on the draft LCDs from July 8 to August 25.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.